SWAG vs. OPRX, TETE, NOTV, YYGH, PSQH, VCSA, FORA, MOBQ, JUNE, and BGSF
Should you be buying Stran & Company, Inc. stock or one of its competitors? The main competitors of Stran & Company, Inc. include OptimizeRx (OPRX), Technology & Telecommunication Acquisition (TETE), Inotiv (NOTV), YY Group (YYGH), PSQ (PSQH), Vacasa (VCSA), Forian (FORA), Mobiquity Technologies (MOBQ), Junee (JUNE), and BGSF (BGSF). These companies are all part of the "business services" industry.
Stran & Company, Inc. vs.
Stran & Company, Inc. (NASDAQ:SWAG) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership.
Stran & Company, Inc. has a net margin of 0.00% compared to OptimizeRx's net margin of -27.41%. Stran & Company, Inc.'s return on equity of 0.00% beat OptimizeRx's return on equity.
OptimizeRx has a consensus target price of $10.42, suggesting a potential upside of 135.67%. Given OptimizeRx's stronger consensus rating and higher probable upside, analysts plainly believe OptimizeRx is more favorable than Stran & Company, Inc..
56.4% of Stran & Company, Inc. shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 53.4% of Stran & Company, Inc. shares are owned by company insiders. Comparatively, 6.1% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, OptimizeRx had 12 more articles in the media than Stran & Company, Inc.. MarketBeat recorded 12 mentions for OptimizeRx and 0 mentions for Stran & Company, Inc.. OptimizeRx's average media sentiment score of 0.19 beat Stran & Company, Inc.'s score of 0.00 indicating that OptimizeRx is being referred to more favorably in the news media.
Stran & Company, Inc. has higher revenue and earnings than OptimizeRx. Stran & Company, Inc. is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.
Stran & Company, Inc. has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
OptimizeRx received 149 more outperform votes than Stran & Company, Inc. when rated by MarketBeat users. Likewise, 63.87% of users gave OptimizeRx an outperform vote while only 60.00% of users gave Stran & Company, Inc. an outperform vote.
Summary
OptimizeRx beats Stran & Company, Inc. on 10 of the 18 factors compared between the two stocks.
Get Stran & Company, Inc. News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWAG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Stran & Company, Inc. Competitors List
Related Companies and Tools
This page (NASDAQ:SWAG) was last updated on 11/21/2024 by MarketBeat.com Staff
